en
Scientific article
English

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Published inThe Lancet Neurology, vol. 12, no. 3, p. 233-243
Publication date2013
Abstract

Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.

Keywords
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease/diagnosis/drug therapy/immunology
  • Amyloid beta-Peptides/blood
  • Area Under Curve
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Immunoglobulins, Intravenous/administration & dosage/adverse effects/blood
  • Male
  • Middle Aged
  • Placebos
  • Severity of Illness Index
Affiliation Not a UNIGE publication
Citation (ISO format)
DODEL, Richard et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. In: The Lancet Neurology, 2013, vol. 12, n° 3, p. 233–243. doi: 10.1016/S1474-4422(13)70014-0
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1474-4422
279views
0downloads

Technical informations

Creation06/27/2018 9:58:00 AM
First validation06/27/2018 9:58:00 AM
Update time03/15/2023 8:28:06 AM
Status update03/15/2023 8:28:05 AM
Last indexation01/17/2024 3:16:40 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack